Related Experiment Video
Updated: Mar 13, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
685
Corticosteroids Mediate Heart Failure-Induced Depression through Reduced σ1-Receptor Expression
Yasuharu Shinoda1, Hideaki Tagashira1, Md Shenuarin Bhuiyan2
1Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-Aoba, Aoba-ku, Sendai, Japan.
Plos One
|October 15, 2016
Summary
Cardiovascular disease in mice leads to depression-like behaviors linked to reduced brain sigma-1 receptor (σ1R) expression. Stimulating σ1R with SA4503 improved both heart function and mood.
Area of Science:
- Neuroscience
- Cardiology
- Pharmacology
Background:
- Cardiovascular diseases are recognized risk factors for human depression.
- Sigma-1 receptor (σ1R) stimulation has shown promise in treating cardiac dysfunction and depression-like behaviors.
Purpose of the Study:
- To investigate the hypothesis that impaired σ1R activity in the brain contributes to depression-like behaviors in animals with cardiovascular disease.
- To explore the therapeutic potential of σ1R stimulation for comorbid cardiac and depressive symptoms.
Main Methods:
- Induction of cardiac hypertrophy and heart failure via transverse aortic constriction (TAC) in mice.
- Assessment of depression-like behaviors, brain σ1R expression (particularly in astrocytes), and plasma corticosterone levels.
- Pharmacological intervention using the σ1R agonist SA4503 and the glucocorticoid receptor antagonist mifepristone.
Main Results:
- TAC-induced heart failure was associated with depression-like behaviors and decreased astrocytic σ1R expression in the hippocampus.
- SA4503 administration ameliorated depression-like behaviors and restored astrocytic σ1R levels.
- Elevated corticosterone levels correlated with depression-like behaviors and reduced hippocampal σ1R expression, effects partially reversed by mifepristone.
Conclusions:
- Impaired brain σ1R activity, potentially triggered by elevated corticosterone, contributes to depression-like behaviors in heart failure.
- σ1R stimulation represents a promising therapeutic strategy for addressing both cardiac dysfunction and associated depression.
More Related Videos
05:28A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice
Published on: May 15, 2019
23.7K
06:55An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
Published on: December 2, 2015
23.6K
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:30Heart Failure V: Medical Management
459
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:17Pathophysiology of Heart Failure
4.3K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.3K